Pfizer’s (PFE) Buy Rating Reaffirmed at BMO Capital Markets
BMO Capital Markets restated their buy rating on shares of Pfizer, Inc. (NYSE:PFE) in a research note published on Thursday. The firm currently has a $39.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $37.00.
A number of other analysts have also recently issued reports on the company. Jefferies Group LLC set a $38.00 target price on Pfizer and gave the stock a neutral rating in a report on Monday. Deutsche Bank AG set a $38.00 price target on Pfizer and gave the stock a buy rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered Pfizer from a buy rating to a hold rating in a research report on Wednesday, October 11th. Barclays PLC set a $38.00 target price on Pfizer and gave the company a buy rating in a research report on Wednesday, October 11th. Finally, ValuEngine raised Pfizer from a hold rating to a buy rating in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $38.26.
Pfizer (NYSE:PFE) traded up 0.50% during midday trading on Thursday, hitting $36.42. 17,502,245 shares of the stock were exchanged. The firm has a 50-day moving average price of $35.56 and a 200-day moving average price of $33.83. The stock has a market cap of $216.60 billion, a P/E ratio of 26.64 and a beta of 1.00. Pfizer has a one year low of $29.83 and a one year high of $36.60.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.64 EPS. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer will post $2.56 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/pfizers-pfe-buy-rating-reaffirmed-at-bmo-capital-markets/1644486.html.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.51%. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 over the last three months. Insiders own 0.06% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Northstar Group Inc. lifted its holdings in Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. raised its holdings in Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares in the last quarter. River Wealth Advisors LLC raised its holdings in Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC raised its holdings in Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 68.98% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.